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An 84-year-old female resident of a residential care facility (RCF) was 
referred for a residential medication management review (RMMR). 
The RMMR was requested as the resident had been wandering much 
more frequently than usual, and staff were finding managing her 
behaviour to be increasingly challenging.
The resident’s medical history was 




•	 gastric ulcer (15 years ago)
•	 lacunar stroke (three years ago)
•	 lung cancer (right partial 
pneumonectomy eight years ago).
Her medications were as follows:
•	 aspirin 100 mg in the morning
•	 calcium carbonate/colecalciferol 
1500 mg/12.5 mcg at night
•	 docusate and senna 50/8 mg two at 
night
•	 dothiepin 75 mg at night (increased 
from 25 mg six months ago)
•	 esomeprazole 20 mg at night
•	 Centrum multivitamin in the morning
•	 olanzapine 2.5 mg at night (changed 
from risperidone three weeks ago)
•	 paracetamol SR 665 mg two when 
required for shoulder pain (less than 
once per fortnight)
•	 salbutamol 100 mcg inhaler used 
when required (used daily after 
showering).
The RCF staff reported that her 
wandering commenced a few months 
ago, and at the time of the RMMR she 
was spending most of the day walking 
seemingly without purpose throughout 
the RCF. She was frequently going 
into the rooms of other residents and, 
three weeks prior to the RMMR, caused a 
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LEARNiNG OBJECTiVES
after reading this article, pharmacists should be 
able to:
•	 recognise the incidence and risks of wandering 
in elderly patients with dementia
•	 identify potential medicine- and non-medicine-
related causes of wandering in patients with 
dementia
•	 discuss the potential for optimisation of medicine 
management which could reduce the incidence 
of wandering and associated risks.
Competency standards (2010) addressed: 2.2, 2.3, 
6.1, 6.2, 7.1.
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great disturbance by entering a room 
where another resident was dying in 
the presence of their family. At this 
time, she was taking risperidone for the 
wandering, but that was changed to 
olanzapine because of a lack of response 
to risperidone. Staff commented that 
the olanzapine did not seem to be any 
more effective than the risperidone.
The only other change to her medication 
regimen in the 12 months before the 
RMMR was an increase in the dose of 
dothiepin (from 25 mg daily) around 
six months prior, following a Cornell 
score of 15 at her annual assessment. 
Her score for the Mini Mental State 
examination (MMSe) at this time 
was 16/30.*
She had been assessed for many 
common precipitants for her changed 
behaviour, with infection, pain and 
constipation all being excluded. 
Changes to her environment did not 
greatly improve her behaviour, and staff 
believed that she did not appear to be 
wandering from boredom. Results of 
blood tests performed a fortnight 
before the RMMR are shown in Table 1. 
At this time, her blood pressure was 
108/55 mmHg, pulse 73 bpm, and she 
weighed 53 kg. 
Assessment
Although a number of issues were 
identified in this RMMR, this paper will 
only discuss the management of the 
resident’s wandering as this was the 
reason for the RMMR referral. Wandering 
is a frequently occurring behavioural 
disorder in people with dementia, 
and is reported to affect 17–63% of 
people with dementia at some time.3 
The term describes a constellation of 
behaviours that are generally accepted 
to involve locomotion without an 
apparent purpose. Wandering is often 
described in terms of other behavioural 
symptoms associated with dementia, 
such as non-aggressive agitation and 
restlessness, although in strict terms 
wandering is a distinct construct.4 
The aetiology of wandering is 
largely unknown, with potential 
influences hypothesised to include 
pathophysiological changes 
(e.g. disrupted parietal lobe function 
and spatial perception), psychosocial 
factors (e.g. internal discomfort from 
pain or constipation) and environmental 
precipitants (such as an inability to 
wayfind).3 Wandering is associated with 
several adverse outcomes for people 
with dementia, including an increased 
risk of falls, injury and weight loss.3 
Wandering has been described as one of 
the most challenging and problematic 
behavioural changes associated with 
dementia.4 Current management 
guidelines recommend an initial 
assessment to identify potential 
causes of the behaviour, based on a 
strong understanding of the person 
with dementia and identification of 
causative factors for wandering.4 In this 
case, many common contributors 
have already been excluded, such as 
pain, constipation and inappropriate 
environment. Interestingly, depression is 
associated with increased wandering,3 
so it is possible that for the resident in 
this case, depression may have been 
contributing if her antidepressant 
therapy was inadequate. 
An investigation of potential 
drug-induced causes of changed 
behaviour in a person with dementia 
is considered to be essential in most 
situations.4 In this case, there was a 
high probability that several medicines 
were either causing or exacerbating the 
resident’s wandering. Of particular note 
is the use of dothiepin for depression. 
As with other tricyclic antidepressants 
(TCAs), dothiepin possesses 
anticholinergic activity, which is 
*the Cornell scale for depression in dementia (Csdd) is designed to assess for the presence of depression in older people with dementia whose ability to 
communicate their basic needs is maintained. depressive symptoms are suggested by a total score of 8 or more. the mini mental state examination (mmse) is an 
assessment of cognitive function and provides an indication of the severity of cognitive impairment. people with mild alzheimer’s disease typically score at least 21 on 
the mmse, 10–20 for moderate disease, and 9 or less for severe disease.1,2
table 1. laboratory results from two weeks ago
















•	 red cell count
•	 mean corpuscle volume
•	 red cell distribution width































•	 tsh 0.40–4.00 mu/l 3.34
Blood sugar level
•	 fasting 4.0–7.0 mmol/l 5.8
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associated with an increased risk of 
confusion and cognitive impairment 
in older people,5 particularly those 
with pre-existing dementia. 
The resident’s wandering worsened 
following the increased dothiepin 
dose, which increased suspicion that 
dothiepin was primarily responsible for 
the resident’s changed behaviour.
A second potential cause was that 
the wandering was associated with 
untreated vitamin B12 deficiency. 
Whilst the most common manifestation 
of vitamin B12 deficiency is 
megaloblastic anaemia, vitamin B12 is 
also necessary for the development 
and maintenance of myelination of 
neurons of the central nervous system 
(CNS).6 Central neurological symptoms 
of vitamin B12 deficiency include 
altered mental status, cognitive defects 
and a constellation of psychological 
symptoms sometimes referred to as 
‘megaloblastic madness’ (depression, 
mania, irritability, paranoia, delusions 
and emotional lability).6 
Whilst the resident’s total vitamin B12 
level was within the reference range, her 
holotranscobalamin level (often referred 
to as ‘active B12’) was low, which is 
consistent with vitamin B12 deficiency.
7 
Holotranscobalamin is considered to 
be a much more sensitive laboratory 
marker of early B12 deficiency than total 
B12 levels, as circulating levels decline 
much more quickly than total levels 
in deficiency states. Most Australian 
pathology laboratories now report 
holotranscobalamin levels in all 
patients with total B12 levels of less than 
200 pmol/L to assist in the interpretation 
of low and low-normal total B12 results. 
Holotranscobalamin levels below 
25 pmol/L are considered to indicate 
vitamin B12 deficiency.
7 In this resident’s 
case, her low holotranscobalamin level, 
macrocytic anaemia and neurological 
symptoms are strongly suggestive of 
vitamin B12 deficiency. 
Vitamin B12 deficiency is caused by 
either inadequate dietary intake or 
malabsorption.6 Inadequate intake most 
frequently occurs in people who eat a 
vegan or vegetarian diet, or a diet low in 
meat and dairy products. Malnutrition 
can occur in people with dementia 
who wander, as the person’s constant 
movement may interrupt eating,3 
which may result in vitamin deficiencies 
if nutrition is not appropriately 
managed. There are a number of 
potential causes of vitamin B12 
malabsorption, including autoimmune 
gastritis (pernicious anaemia), gastric 
bypass surgery and atrophic gastritis.8 
Medicines such as metformin and 
proton pump inhibitors (PPIs) have also 
been associated with causing vitamin 
B12 deficiency,
6,8 and this resident’s use 
of esomeprazole may have contributed 
to her deficiency. 
A related concern regarding this 
resident’s medicine management is 
the use of antipsychotic treatment as 
part of the management strategy for 
her wandering. Firstly, wandering is 
not considered to be a behaviour 
that justifies the use of antipsychotic 
medicine.4 Although it may be 
perceived by others as annoying, 
wandering is unlikely to cause harm to 
others, and can be managed through 
basic behavioural techniques or 
environmental changes. These strategies 
avoid exposing people to adverse 
effects associated with medicines used 
for behavioural symptoms of dementia 
such as antipsychotics. Of particular 
concern with the use of antipsychotics 
for wandering is that antipsychotic use 
is associated with causing akathisia,9 
a feeling of motor restlessness that 
may exacerbate wandering behaviour. 
Furthermore, as the onset of akathisia 
may be delayed by several days, 
the association between the worsening 
wandering and antipsychotic use may 
not be recognised.4 For the resident 
discussed in this case study, there seems 
to be little justification for the use of 
olanzapine, as it is ineffective at best 
and may actually be aggravating the 
target behaviour.
Recommendations
A number of recommendations 
were made in the RMMR report to 
optimise this resident’s medicine 
management. In consideration of the 
potential for dothiepin to exacerbate 
the resident’s wandering, it was 
suggested to withdraw dothiepin and 
commence sertraline. Although there 
is a lack of evidence of clear benefit 
of antidepressants for people with 
dementia,10,11 it was considered that 
antidepressant treatment was desirable 
due to the potential for depression to 
be affecting the resident’s behaviour. 
As sertraline may cause syndrome of 
inappropriate antidiuretic hormone 
secretion (SIADH) and the resident 
had existing mild hyponatraemia,9 
intermittent monitoring of her serum 
sodium level was also suggested. 
Further recommendations included 
the cessation of olanzapine through 
a dose-tapering regimen, based 
on its lack of effectiveness and 
potential to exacerbate wandering. 
Commencement of parenteral vitamin 
B12 supplementation was also advised; 
whilst it would have been ideal to cease 
esomeprazole, this was not considered 
to be appropriate due to the resident’s 
history of a gastric ulcer and ongoing 
antiplatelet therapy.
“an investigation of potential drug-induced causes of 
changed behaviour in a person with dementia is considered 
to be essential in most situations.”
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1. which one of the following tests 
is used to screen for depression in 
people with dementia?
a) mini mental state examination (mmse).
b) Cornell scale for depression in 
dementia (Csdd).
c) behaviour rating scale for dementia 
(brsd).
d) hierarchic dementia scales - revised 
(hds-r).
2. which one of the following 
statements regarding wandering is 
the most appropriate?
a) wandering is rarely observed in people 
with dementia.
b) wandering is synonymous with non-
aggressive agitation. 
c) wandering may be precipitated by 
inappropriate environment. 
d) wandering is generally straightforward 
to manage with antipsychotics.
3. By which one of the following 
mechanisms is dothiepin least likely 
to cause or exacerbate wandering?
a) antidepressant effect. 
b) Central anticholinergic effects.
c) induction of constipation.
d) sedative activity.
4. which one of the following 
laboratory tests is least useful for 
identifying B
12
 deficiency in a person 









5. a 78-year-old with advanced 
dementia is admitted to an 
rcf because his family can no 
longer manage his incessant 
wandering. which one of the 
following statements regarding 
his management is the least 
appropriate?
a) his weight should be monitored to 
ensure he is adequately nourished.
b) his risk factors for falls should be 
identified and managed. 
c) his medicines should be reviewed to 
identify potential drug-induced causes 
of wandering.
d) he should be physically restrained to 
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